An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With Rituximab (MabThera) in Patients With Follicular Non Hodgkin's Lymphoma With no Prior Treatment
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Rituximab; Sargramostim
- Indications Non-Hodgkin's lymphoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Jul 2012 Companies added in the association field as reported by EudraCT.
- 04 Jul 2012 Actual initiation date 19 Sep 2008 added as reported by EudraCT.